These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 29938908)
1. Atypical Antipsychotic Administration in Schizophrenic Patients Leads to Elevated Lipoprotein-Associated Phospholipase A2 Levels and Increased Cardiovascular Risk: A Retrospective Cohort Study. Shen H; Wu D; Wang S; Zhao M; Sun W; Zhu X; Zhang N; Yao H; Cui Q; Xiao H Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):756-765. PubMed ID: 29938908 [TBL] [Abstract][Full Text] [Related]
2. Quetiapine versus other atypical antipsychotics for schizophrenia. Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315 [TBL] [Abstract][Full Text] [Related]
3. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Krzystanek M; Krupka-Matuszczyk I Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416 [TBL] [Abstract][Full Text] [Related]
4. Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies. Dias Alves M; Micoulaud-Franchi JA; Simon N; Vion-Dury J J Clin Psychopharmacol; 2018 Dec; 38(6):555-562. PubMed ID: 30247179 [TBL] [Abstract][Full Text] [Related]
5. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516 [TBL] [Abstract][Full Text] [Related]
6. Lipoprotein-associated phospholipase A2 predicted cardiovascular disease in obstructive sleep apnea syndrome. Xu C; Yu F; Mao S; Shi Y; Li Q; Fang S; Tan Y; Gu W; Ye L Respir Med; 2020 Mar; 163():105881. PubMed ID: 32056835 [TBL] [Abstract][Full Text] [Related]
7. Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine. Osborn D; Marston L; Nazareth I; King MB; Petersen I; Walters K Schizophr Res; 2017 May; 183():116-123. PubMed ID: 27884434 [TBL] [Abstract][Full Text] [Related]
8. [Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone]. Bret P; Bonnet F; Bret MC; Jaffré A Encephale; 2002; 28(4):329-42. PubMed ID: 12232542 [TBL] [Abstract][Full Text] [Related]
10. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Garza CA; Montori VM; McConnell JP; Somers VK; Kullo IJ; Lopez-Jimenez F Mayo Clin Proc; 2007 Feb; 82(2):159-65. PubMed ID: 17290721 [TBL] [Abstract][Full Text] [Related]
11. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Persson M; Hedblad B; Nelson JJ; Berglund G Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1411-6. PubMed ID: 17431184 [TBL] [Abstract][Full Text] [Related]
12. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Lee SY; Park MH; Patkar AA; Pae CU Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575 [TBL] [Abstract][Full Text] [Related]
13. Lipoprotein-Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China. Wang C; Fang X; Hua Y; Liu Y; Zhang Z; Gu X; Wu X; Tang Z; Guan S; Liu H; Liu B; Guo X; Ji X Angiology; 2018 Jan; 69(1):49-58. PubMed ID: 28429599 [TBL] [Abstract][Full Text] [Related]
14. Interrelationships among platelet-activating factor and lipoprotein-associated phospholipase A English CJ; Lohning AE; Mayr HL; Jones M; Reidlinger DP Biofactors; 2023 Mar; 49(2):457-471. PubMed ID: 36538603 [TBL] [Abstract][Full Text] [Related]
15. [Metabolic side effects of risperidone in early onset schizophrenia]. Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267 [TBL] [Abstract][Full Text] [Related]
16. The Utility of the Lipoprotein-Associated Phospholipase A Mayne ES; Moabi H; Grobbee DE; Barth RE; Klipstein-Grobusch K; Stevens WS; Vos AG; Louw S Clin Appl Thromb Hemost; 2019; 25():1076029619883944. PubMed ID: 31686546 [TBL] [Abstract][Full Text] [Related]
17. Metabolic risk factors in schizophrenia and bipolar disorder: The effect of comedication with selective serotonin reuptake inhibitors and antipsychotics. Fjukstad KK; Engum A; Lydersen S; Dieset I; Steen NE; Andreassen OA; Spigset O Eur Psychiatry; 2018 Feb; 48():71-78. PubMed ID: 29331603 [TBL] [Abstract][Full Text] [Related]
18. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820 [TBL] [Abstract][Full Text] [Related]
19. Correlation between smoking and serum lipoprotein-associated phospholipase A2 level in overweight and obese men. Zhou H; Zhao L Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Feb; 48(2):191-197. PubMed ID: 36999465 [TBL] [Abstract][Full Text] [Related]
20. Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia. Lin Y; Peng Y; He S; Xu J; Shi Y; Su Y; Zhu C; Zhang X; Zhou R; Cui D Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):71-78. PubMed ID: 29410009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]